PPARG and breast carcinoma: Recently it has been demonstrated that PPAR γ agonists 15d-PGJ(2) and rosiglitazone significantly reduced eosinophil migration into the peritoneal cavity [30] and that ciglitazone reduced both wound-induced migration and chemotaxis of breast cancer cells [31] in a PPARγ-dependent and PPARγ-independent manner.